EMD-24346

Single-particle
15.0 Å
EMD-24346 Deposition: 30/06/2021
Map released: 04/08/2021
Last modified: 10/11/2021
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-24346

Negative stain EM map of SARS-CoV-2 Spike in complex with CoVIC-80 IgG

EMD-24346

Single-particle
15.0 Å
EMD-24346 Deposition: 30/06/2021
Map released: 04/08/2021
Last modified: 10/11/2021
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus 2
Sample: The complex of SARS-CoV-2 Spike and CoVIC-80 IgG

Deposition Authors: Saphire EO, Li H
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.
PUBMED: 34554826
DOI: doi:10.1126/science.abh2315
ISSN: 1095-9203
ASTM: SCIEAS
Abstract:
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.